Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PPD’s Reputation Ranked Best of all CROs in Global Survey

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
No. 1 for innovation in improving site relationships and use of technology, data analytics.

Pharmaceutical Product Development, LLC (PPD) announced that clinical research sites globally ranked the company No. 1 for reputation among all contract research organizations (CROs) in CenterWatch’s 2013 Global Investigative Site Relationship Survey.

PPD also ranked second on investigative sites’ evaluation of their clinical trial relationships with CROs. Overall, PPD was ranked in the top three CROs on all 36 relationship attributes that the questionnaire asked of clinical research professionals at investigative sites globally.

Not only did four of every five survey respondents say PPD had an excellent or good reputation, PPD also ranked best in “being an innovator in finding ways to improve its relationships with sites and using technology to make processes more efficient, [using] data analytics to help target where sites might have a potential issue,” according to The CenterWatch Monthly, which published the survey results today. “PPD uses its analytics to improve productivity and quality across all project functions, not just monitoring.”

Clinical research professionals at 2,032 global sites completed the biennial survey, the largest CenterWatch has conducted to measure the quality of working relationships between CROs and sites conducting clinical research.

“These survey results are a real testament to the quality of the staff at PPD,” said Paul Colvin, PPD’s executive vice president, global clinical development. “We work to hire, train and retain the best team in the industry. We feel that trust, accountability, performance and results are the basis of PPD’s strong reputation within the industry and the foundation of our relationships with our biopharmaceutical clients and our investigative sites.

“Investigative sites are critical partners in clinical research,” Colvin said. “And strong site relationships are vital to our efforts to bend the cost and time curve of drug discovery and development to help our clients deliver life-changing medical therapies to the market faster, more cost effectively and with the highest possible quality.”

PPD’s best ranking for industry reputation follows its top overall CRO ranking in 2011, the last time CenterWatch conducted the global survey. PPD was rated highest in multiple categories that year, including staff professionalism, good protocol design, study initiation, being organized and prepared, and setting realistic project timelines. PPD also was rated one of Europe’s top CROs in the 2010 CenterWatch European Site Survey.

Since 1994, CenterWatch has been a global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals, ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PPD Awarded U.S. Army and BARDA Research Contracts
Providing clinical development and vaccine services.
Friday, October 16, 2015
PPD Collaborates with CISYS LifeSciences
Sequence WebEAS helps PPD’s clients reduce effort and cost associated with administering adjudications.
Friday, September 11, 2015
PPD and HealthCore Collaborate
Goal is to establish new quality, cost and speed benchmarks for creating real-world clinical and economic evidence.
Friday, June 19, 2015
PPD Laboratories Opens Central Lab in Shanghai, China
Provides clients with broad range of standardized lab testing services and capabilities.
Friday, April 24, 2015
PPD and SNBL Complete Joint Venture
Joint venture to provide Japanese clinical development services and additional collaborations.
Friday, April 17, 2015
PPD Expands GMP Laboratory in Athlone, Ireland
Analytical testing facility adds cell-based lab capabilities.
Thursday, January 22, 2015
PPD Acquires RCT Logic’s Exclusive License to Patented Clinical Trial Design Technology
Expands PPD’s clinical development capabilities, particularly in neuroscience.
Thursday, September 04, 2014
PPD and Charité-Universitätsmedizin Berlin Announce Strategic Collaboration
Additional clinical trials to enhance health care delivery.
Saturday, March 01, 2014
PPD Acquires Acurian
Strengthens PPD’s comprehensive suite of feasibility, patient recruitment and retention services.
Thursday, August 29, 2013
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!